AI-Powered Heart Failure Research

Heart failure affects 6.7 million Americans and is the leading cause of hospitalization over age 65. AI agents research SGLT2 inhibitors, gene therapy, and cardiac regeneration.

Standard of Care

Quadruple therapy for HFrEF: SGLT2i + ARNI (sacubitril/valsartan) + beta-blocker + MRA. For HFpEF: SGLT2 inhibitors (empagliflozin/dapagliflozin). Cardiac resynchronization, ICD, LVAD, heart transplant for advanced cases.

Prevalence

~6.7 million Americans. ~1 million new diagnoses/year. 5-year mortality ~50%.

Key Biomarkers

• NT-proBNP / BNP
• Ejection fraction (echo)
• Troponin (myocardial injury)
• Galectin-3 (fibrosis)
• sST2 (cardiac stress)

Emerging Research

SGLT2 inhibitors effective across the entire HF spectrum (HFrEF, HFmrEF, HFpEF). Gene therapy for genetic cardiomyopathies (MYBPC3, TTN mutations). Cardiac stem cell/progenitor cell therapy. Artificial hearts becoming bridge-to-transplant standard. GLP-1 agonists showing HF benefit in obesity-HFpEF overlap.

Frequently Asked Questions

What is the quadruple therapy for heart failure?

Modern HFrEF treatment uses four drug classes simultaneously: (1) SGLT2 inhibitor, (2) ARNI (sacubitril/valsartan), (3) beta-blocker, and (4) mineralocorticoid receptor antagonist (MRA). This combination reduces mortality by ~60% vs placebo. Early initiation and rapid titration are emphasized in current guidelines.

Can the heart regenerate?

Adult human hearts have very limited regenerative capacity (~1%/year cardiomyocyte turnover). Research focuses on: reactivating cardiomyocyte proliferation (YAP/Hippo pathway), direct cardiac reprogramming (fibroblasts → cardiomyocytes), and stem cell-derived cardiomyocyte patches. These approaches aim to restore function after myocardial infarction.